Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications
Phase I first-in-human dose escalation study of the oral casein kinase 1α and cyclin dependent kinase 7/9 inhibitor BTX A51 in advanced MDS and AML.
Journal: Journal of hematology & oncology
Published: May 06, 2025
Phase I First-in-Human Dose Escalation Study of the oral Casein Kinase 1α and Cyclin Dependent Kinase 7/9 inhibitor BTX-A51 in advanced MDS and AML.
Journal: Research square
Published: November 01, 2024
Oral PD-L1 inhibitor GS-4224 selectively engages PD-L1 high cells and elicits pharmacodynamic responses in patients with advanced solid tumors.
Journal: Journal for immunotherapy of cancer
Published: March 01, 2024
Publisher Correction: Glucagon receptor antagonist volagidemab in type 1 diabetes: a 12-week, randomized, double-blind, phase 2 trial.
Journal: Nature medicine
Published: March 18, 2023
Safety and tolerability of andecaliximab as monotherapy and in combination with an anti-PD-1 antibody in Japanese patients with gastric or gastroesophageal junction adenocarcinoma: a phase 1b study.
Journal: Journal for immunotherapy of cancer
Published: November 20, 2021
Randomized, open-label, phase 2 study of andecaliximab plus nivolumab versus nivolumab alone in advanced gastric cancer identifies biomarkers associated with survival.
Journal: Journal for immunotherapy of cancer
Published: October 05, 2021
Targeting the glucagon receptor signaling pathway as a novel strategy to counteract PI3K inhibitor induced hyperglycemia while sustaining tumor PI3K inhibition.
Journal: Leukemia & lymphoma
Published: February 12, 2021
Phase III Study to Evaluate Efficacy and Safety of Andecaliximab With mFOLFOX6 as First-Line Treatment in Patients With Advanced Gastric or GEJ Adenocarcinoma (GAMMA-1).
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: February 12, 2021
Safety and Efficacy of Andecaliximab (GS-5745) Plus Gemcitabine and Nab-Paclitaxel in Patients with Advanced Pancreatic Adenocarcinoma: Results from a Phase I Study.
Journal: The oncologist
Published: May 22, 2020
Targeting the glucagon receptor improves cardiac function and enhances insulin sensitivity following a myocardial infarction.
Journal: Cardiovascular diabetology
Published: November 10, 2018
Last Updated: 09/26/2026